株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

皮膚疾患治療薬の世界市場:2017年〜2027年の予測

Dermatological Drugs Market Forecast 2017-2027: Psoriasis, Skin Infection, Acne, Dermatitis, Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer, LEO Pharma

発行 Visiongain Ltd 商品コード 233143
出版日 ページ情報 英文 295 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=154.30円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
皮膚疾患治療薬の世界市場:2017年〜2027年の予測 Dermatological Drugs Market Forecast 2017-2027: Psoriasis, Skin Infection, Acne, Dermatitis, Humira, Stelara, Enbrel, Remicade, Taltz, Cosentyx, Cubicin, Canesten, Epiduo, Bepanthen, Elocon, Galderma, Johnson & Johnson, AbbVie, GSK, Pfizer, LEO Pharma
出版日: 2017年07月06日 ページ情報: 英文 295 Pages
概要

世界の皮膚疾患治療薬の市場は、2016年には256億5000万米ドルを記録し、調査期間前半にかけて4.5%の複合年間成長率(CAGR)で推移するものと予測されています。

当レポートでは、世界の皮膚疾患治療薬の市場を調査し、皮膚医学の概要、一般的な皮膚疾患の種類と概要、疾患区分別の治療薬市場の最新動向、市場規模の推移と予測、主な治療薬のプロファイル、主要地域および国別の動向、開発パイプラインの動向、主要企業のプロファイルなどをまとめています。

第1章 レポート概要

第2章 皮膚疾患治療薬:イントロダクション

  • 医薬品産業:概要
  • 皮膚医学の概要
    • 皮膚・毛髪・爪の構造
    • 毛髪と爪
    • 汗腺と脂腺
    • 皮膚の機能
  • 一般的な皮膚疾患
    • 座瘡 (にきび):もっとも一般的な皮膚疾患
    • 皮膚炎:皮膚の炎症
      • アトピー性皮膚炎
      • 接触性皮膚炎 (CD)
      • 脂漏性皮膚炎
      • 貨幣状皮膚炎
      • 口囲皮膚炎
    • 乾癬:複雑な多因子性疾患
    • 酒さ:血管不安定性
    • 脱毛症:異常な抜け毛
  • 皮膚感染:深刻な健康上の脅威
    • 細菌性皮膚感染
    • 菌性皮膚感染
    • ウィルス性皮膚感染
  • 一般的な皮膚疾患治療薬
    • クリーム・半固形乳剤
    • 軟膏
    • ローション
    • 液剤
    • 密封療法
    • 洗浄剤
    • 粉末・親水性ポリマー
    • 抗感染症剤
    • 抗炎症剤
  • 臨床試験のフェーズ
  • 皮膚疾患治療薬:本書での市場の定義

第3章 世界の皮膚疾患治療薬市場の予測

  • 市場概要
  • 皮膚疾患治療薬のカテゴリー区分
  • 市場実績
  • 市場予測
  • 部門別の市場シェアの予測

第4章 乾癬治療薬市場の分析・予測

  • 乾癬治療薬:主流の生物製剤
    • 主要製品
  • 市場動向・発展動向
  • 市場予測
  • 主な薬剤
    • Humira (アダリムマブ:Abbott)
    • Stelara (ウステキヌマブ:Johnson & Johnson)
    • Enbrel (エタネルセプト:Amgen・Pfizer・武田薬品工業)
    • Remicade (インフリキシマブ:Johnson & Johnson)
    • Taltz (イキセキズマブ:Eli Lily)
    • Otezla (アプレミラスト:Celgene)
    • Cosentyx (セクキヌマブ:Novartis)
    • その他
  • サマリー

第5章 皮膚感染症治療薬市場の分析・予測

  • 皮膚感染治療薬:豊富な成長機会
    • 主要製品
  • 市場予測
  • 主な薬剤
    • Cubicin(ダプトマイシン:Cubist Pharmaceuticals・Merck & Co)
    • Acquisition(Merck & Co)
    • ジェネリック医薬品の参入によるCubicinの競合
    • Cubicin:売上予測
    • Cubicin:ライフサイクル管理における戦略
  • Zyvox (リネゾリド:Pfizer)
  • Canesten (クロトリマゾール:Bayer)
  • Valtrex (バラシクロビル:GSK)
  • Bactroban (ムピロシン:GSK)
  • Lamisil (テルビナフィン:Novartis)
  • その他
  • サマリー

第6章 座瘡治療薬市場の分析・予測

  • 座瘡治療薬:多様化する市場
    • 主要製品
  • 近年の動向・発展動向
  • 市場予測
  • 主な薬剤
    • Epiduo (アダパレン/過酸化ベンゾイル:Galderma・Nestle Skin Health)
    • Solodyn (ミノサイクリン:Valeant)
    • Claravis (イソトレチノイン:Teva)
    • Aczone (ダプソン:Allergan)
    • Differin (アダパレン:Galderma/Nestle Skin Health)
    • Absorica/Epuris (CIPイソトレチノイン:Cipher/ Sun Pharma)
    • Ziana (トレチノイン・クリンダマイシン:Valeant)
    • Doryx (ドキシサイクリン塩酸塩:Actavis/ Mayne Pharma)
    • その他
  • サマリー

第7章 皮膚炎治療薬市場の分析・予測

  • 皮膚炎治療薬:ジェネリック薬の高い普及率
    • 主要製品
  • 市場予測
  • 主な薬剤
    • Bepanthen (デクスパンテノール:Bayer)
    • Elocon (フランカルボン酸モメタゾン:Merck & Co)
    • Protopic (タクロリムス:LEO Pharma)
    • Dermovate (GSK)
    • その他
  • 市場の展望

第8章 主要国市場の予測

  • 地域別市場
  • 主要国市場の予測
    • 市場シェアの推移と予測
  • 市場分析・予測:地域別
    • 米国
    • EU5カ国
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
    • 日本
    • 中国
    • インド
    • ブラジル
    • ロシア
    • その他

第9章 主要企業

  • 皮膚疾患治療薬:統合化の進む市場
  • Galderma
  • Johnson & Johnson
  • AbbVie
  • GlaxoSmithKline
  • Pfizer
  • LEO Pharma

第10章 R&Dパイプラインの予測

  • 開発中の革新的製品:今後の市場成長を推進
  • 乾癬治療薬のパイプライン
  • 皮膚感染症治療薬のパイプライン
  • 座瘡治療薬のパイプライン
  • 皮膚炎治療薬のパイプライン
  • その他の治療薬のパイプライン

第11章 定性分析

  • 市場への影響因子
  • SWOT分析
  • ファイブフォース分析

第12章 インタビュー概要

第13章 総論

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0209

The revenue of the dermatological drugs market in 2016 is estimated at $25.65bn and is expected to grow at a CAGR of 4.5% in the first half of the forecast period. Psoriasis drugs accounted for the largest share of the market in 2016, this segment generated $9.23bn.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 295-page report you will receive 111 tables and 92 figures - all unavailable elsewhere.

The 295-page report provides clear detailed insight into the dermatological drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Dermatological drugs market forecasts from 2017-2027
  • This report also breaks down the revenue forecast for the main submarkets:
    • Psoriasis
    • Skin Infections
    • Acne
    • Dermatitis
  • Analysis of the Psoriasis drugs market. Revenue forecasts to 2027 are provided for the following drugs:
    • Humira
    • Stelara
    • Enbrel
    • Remicade
    • Taltz
    • Otezla
    • Cosentyx
  • Analysis of the Skin Infections drugs market. Revenue forecasts to 2027 are provided for the following drugs:
    • Cubicin
    • Zyvox
    • Valtrex
    • Canesten
    • Lamisil
    • Bactroban
  • Analysis of the Acne drugs market. Revenue forecasts to 2027 are provided for the following drugs:
    • Solodyn
    • Epiduo
    • Claravis
    • Aczone
    • Differin
    • Abscorical/Epirus
    • Ziana
    • Doryx

image1

  • Analysis of the Dermatitis drugs market. Revenue forecasts to 2027 are provided for the following drugs:
    • Bepanthen/Bepanthol
    • Protopic
    • Dermovate
    • Elocon
  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • US
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Japan
    • China
    • Brazil
    • Russia
    • India
    • Rest of World
  • This report provides discussion on pipeline products in various stages of clinical trials and regulatory approval.
  • Our study includes SWOT analysis and Porter's Five Force analysis of the dermatological drugs market.
  • Two interviews conducted by Visiongain with experts in the dermatological drugs market:
  • Interview with Dr Michael Siegel, Vice President of Research Programs at National Psoriasis Foundation
  • Interview with Guillaume Clement, Executive Vice President, Region EUROPE+, LEO Pharma
  • Our study discusses the selected leading companies that are the major players in the dermatological drugs market:
    • Galderma (Nestle Skin Health S.A.)
    • Johnson & Johnson
    • AbbVie
    • GlaxoSmithKline (GSK)
    • Pfizer
    • LEO Pharma

Our new report discusses issues and events affecting the dermatological drugs market:

  • Highly fragmented and competitive market with significant variations in different geographic regions
  • Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
  • Future paradigm-shifting pipeline products
  • Patent expirations
  • Launches of new drug categories
  • Biosimilars approvals, Biosimilars interchangeability, Biosimilars guidance

Visiongain's study is intended for anyone requiring commercial analyses for the dermatological drugs market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Global Dermatological Drugs: Market Overview
  • 1.2 Global Dermatological Drugs Market Segmentation
  • 1.3 Overview of Findings
  • 1.4 Structure of the Report
  • 1.5 Why You Should Read This Report
  • 1.6 How This Report Delivers
  • 1.7 Key Questions Answered by This Analytical Report
  • 1.8 Who is This Report For?
  • 1.9 Methodology
  • 1.10 Frequently Asked Questions (FAQ)
  • 1.11 Associated Visiongain Reports
  • 1.12 About Visiongain

2. An Introduction to Dermatological Drugs

  • 2.1 The Pharmaceutical Industry: A Brief Introduction
  • 2.2 An Introduction to Dermatology
    • 2.2.1 The Structure of Skin, Hair, and Nails
    • 2.2.2 Hair and Nails
    • 2.2.3 Sweat and Sebaceous Glands
    • 2.2.4 Functions of the Skin
  • 2.3 Common Skin Diseases
    • 2.3.1 Acne: The Most Common Skin Disease
      • 2.3.1.1 Acne: Epidemiology
      • 2.3.1.2 Acne: Causes and Pathogenesis
      • 2.3.1.3 Acne: Treatment
    • 2.3.2 Dermatitis: Inflammation of the Skin
      • 2.3.2.1 Atopic Dermatitis
      • 2.3.2.2 Contact Dermatitis
      • 2.3.2.3 Seborrhoeic Dermatitis
      • 2.3.2.4 Nummular Dermatitis
      • 2.3.2.5 Perioral Dermatitis
    • 2.3.3 Psoriasis: A Complex Multi-factorial Disease
    • 2.3.4 Rosacea: Vascular Instability
    • 2.3.5 Alopecia: Excessive Shedding Of Hair
  • 2.4 Skin Infections: A Serious Healthcare Threat
    • 2.4.1 Bacterial Skin Infections
    • 2.4.2 Fungal Skin Infections
    • 2.4.3 Viral Skin Infections
  • 2.5 Common Skin Treatments
    • 2.5.1 Creams and Semisolid Emulsions
    • 2.5.2 Ointments
    • 2.5.3 Lotions
    • 2.5.4 Solutions
    • 2.5.5 Occlusive Therapy
    • 2.5.6 Cleansing Agents
    • 2.5.7 Powders and Hydrophilic Polymer
    • 2.5.8 Anti-Infective Agents
    • 2.5.9 Anti-Inflammatory Agents
  • 2.6 Phases of Clinical Trials
  • 2.7 Dermatological Drugs: Market Definition in this Report

3. The Global Dermatological Drugs Market, 2017-2027

  • 3.1 The Global Dermatological Drugs Market: Market Overview
  • 3.2 Categorisation of the Global Dermatological Drugs Market
  • 3.3 The Global Dermatological Drugs Market in 2016
  • 3.4 The Global Dermatological Drugs Market: Market Forecast 2017-2027
  • 3.5 Dermatological Drugs: Changing Market Shares by Sector 2017-2027

4. The Psoriasis Drugs Market: Market Analysis and Forecast 2017-2027

  • 4.1 Psoriasis Treatments: The Dominance of Biologics
    • 4.1.1 Leading Products in the Psoriasis Drugs Market, 2016
  • 4.2 Psoriasis: Market Trends and Developments, 2017
    • 4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview
    • 4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing
    • 4.2.3 Biosimilars and Interchangeables
      • 4.2.3.1 Extrapolation of indications
      • 4.2.3.2 Biosimilar interchangeability in the EU
      • 4.2.3.3 Biosimilar guidance in the US
    • 4.2.4 The Disadvantages of Biologics in Psoriasis Treatment
  • 4.3 Psoriasis Drugs: Market Forecast 2017-2027
    • 4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2016-2027
  • 4.4 Leading Drugs Used in the Treatment of Psoriasis
    • 4.4.1 Humira (adalimumab) - AbbVie
      • 4.4.1.1 Humira: Historical Sales Analysis, 2010-2015
      • 4.4.1.2 Humira: Sales Forecast 2017-2027
      • 4.4.1.3 Future Prospects for Biosimilar Versions of Humira
    • 4.4.2 Stelara (ustekinumab) - Johnson & Johnson
      • 4.4.2.1 Stelara New Market Leader, Ahead of Humira
      • 4.4.2.2 Stelara: Historical Sales Analysis, 2010-2015
      • 4.4.2.3 Stelara: Sales Forecast 2017-2027
      • 4.4.2.4 Intensifying Competition for Stelara
    • 4.4.3 Enbrel (etanercept) - Amgen/ Pfizer/ Takeda
      • 4.4.3.1 Enbrel: Co-Promotions and Marketing Rights
      • 4.4.3.2 Enbrel: Historical Sales Analysis, 2008-2016
      • 4.4.3.3 Enbrel: Patent Expiries and Potential Competition, 2017-2027
      • 4.4.3.4 Patent Litigation with Sandoz Over Enbrel
      • 4.4.3.5 Enbrel: Sales Forecast 2017-2027
      • 4.4.3.6 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years
      • 4.4.3.7 Competition from Other Drugs
      • 4.4.3.8 Biosimilar Competition for Enbrel
    • 4.4.4 Remicade (infliximab) - Johnson & Johnson
      • 4.4.4.1 Remicade: Historical Sales Analysis, 2008-201
      • 4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2017-2027
      • 4.4.4.3 Remicade: Sales Forecast 2017-2027
    • 4.4.5 Taltz (ixekizumab) - Eli Lily
      • 4.4.5.1 Taltz: Sales Forecast 2017-2027
    • 4.4.6 Otezla (apremilast) - Celgene
      • 4.4.6.1 Otezla: Sales Forecast 2017-2027
    • 4.4.7 Cosentyx (secukinumab) - Novartis
      • 4.4.7.1 Cosentyx: Sales Forecast 2017-2027
    • 4.4.8 Other Psoriasis Drugs
      • 4.4.8.1 Cimzia (certolizumab) - UCB
      • 4.4.8.2 Sorilux (calcipotriene foam) - GSK
      • 4.4.8.3 Siliq (brodalumab) - AstraZeneca/ LEO Pharma
      • 4.4.8.3 Other Psoriasis Drugs: Sales Forecast 2017-2027
  • 4.5 Psoriasis Drugs Market: Summary

5. Skin Infection Drugs Market: Market Analysis and Forecast 2017-2027

  • 5.1 Skin Infection Drugs: Abundant Growth Opportunities
    • 5.1.1 Leading Products in the Skin Infection Drugs Market, 2016
  • 5.2 Skin Infection Drugs: Market Forecast 2017-2027
    • 5.2.1 Skin Infection Drugs: Changing Market Shares by Leading Drugs 2017-2027
  • 5.3 Leading Drugs Used in the Treatment of Skin Infections
    • 5.3.1 Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck & Co
    • 5.3.2 Acquisition by Merck & Co
    • 5.3.3 Generic Competition for Cubicin
    • 5.3.4 Cubicin: Sales Forecast 2017-2027
    • 5.3.5 Lifecycle Management Strategies for Cubicin
  • 5.4 Zyvox (linezolid) - Pfizer
    • 5.4.1 Zyvox: Historical Sales Analysis, 2010-2015
    • 5.4.2 Zyvox: Sales Forecast 2017-2027
    • 5.4.3 The Threats to Zyvox Sales from Competing New Drugs
  • 5.5 Canesten (clotrimazole) - Bayer
    • 5.5.1 Canesten: Historical Sales Analysis, 2011-2015
    • 5.5.2 Canesten: Sales Forecast 2017-2027
  • 5.6 Valtrex (valaciclovir) - GSK
    • 5.6.1 Valtrex: Historical Sales Analysis, 2010-2015
    • 5.6.2 Valtrex: Sales Forecast 2017-2027
  • 5.7 Bactroban (mupirocin) - GSK
    • 5.7.1 Bactroban: Historical Sales Analysis, 2010-2013
    • 5.7.2 Bactroban: Sales Forecast 2017-2027
  • 5.8 Lamisil (terbinafine) - Novartis
    • 5.8.1 Lamisil Patent Expiry
    • 5.8.2 Lamisil Sales Affected By Novartis Manufacturing Problems
    • 5.8.3 Lamisil: Sales Forecast 2017-2027
  • 5.9 Other Skin Infection Drugs
    • 5.9.1 Dalvance (dalbavancin) - Durata Therapeutics
    • 5.9.2 Jublia (efinaconazole) - Valeant
    • 5.9.3 Kerydin (tavaborole) - Anacor
    • 5.9.4 Sivextro (tedizolid) - Cubist Pharmaceuticals
    • 5.9.5 Zovirax (acyclovir) - Valeant/GSK
    • 5.9.5.1 Valeant Acquires Zovirax in US and Canada
    • 5.9.5.2 Mylan's Generic Zovirax and Actavis' Authorised Generic
    • 5.9.6 Other Skin Infection Drugs: Sales Forecast 2017-2027
  • 5.10 Skin Infection Drugs: Market Summary

6. Acne Drugs Market: Market Analysis and Forecast 2017-2027

  • 6.1 Acne Drugs: A Diversified Market
    • 6.1.1 Leading Products in the Acne Drugs Market, 2016
  • 6.2 Acne Drugs Market: Recent Trends and Developments
    • 6.2.1 The Rise of Combination Therapies in Acne Treatment
    • 6.2.2 Oral Contraceptives in Treating Acne
    • 6.2.3 The Threat of Generic Competition in the Acne Drugs Market
  • 6.3 Acne Drugs: Market Forecast 2017-2027
    • 6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2016-2027
  • 6.4 Leading Drugs in the Acne Drugs Market
    • 6.4.1 Epiduo (adapalene/benzoyl peroxide) - Galderma/ Nestlé Skin Health
      • 6.4.1.1 Epiduo: Sales Forecast 2017-2027
      • 6.4.1.2 Galderma Settlement Agreement over Generic Epiduo
      • 6.4.1.3 Paediatric Approval for Epiduo
    • 6.4.2 Solodyn (minocycline) - Valeant
      • 6.4.2.1 Solodyn: Sales Forecast 2017-2027
      • 6.4.2.2 Antitrust Action over Solodyn Pay-For-Delay Deals
      • 6.4.2.3 Impax and Medicis Collaborating On Advanced Solodyn
      • 6.4.2.4 Medicis and Lupin Settle
    • 6.4.3 Claravis (isotretinoin) - Teva
      • 6.4.3.1 Claravis: Sales Forecast 2017-2027
    • 6.4.4 Aczone (dapsone) - Allergan
      • 6.4.4.1 Aczone: Sales Forecast 2017-2027
    • 6.4.5 Differin (adapalene) - Galderma/ Nestlé Skin Health
      • 6.4.5.1 Recent Generic Competition to Differin
      • 6.4.5.2 Differin: Sales Forecast 2017-2027
      • 6.4.5.3 Adapalene Gel to be Available OTC in the US
      • 6.4.5.4 Federal Circuit Court Invalidates Differin Patents
    • 6.4.6 Absorica/Epuris (CIP-isotretinoin) - Cipher/Sun Pharma
      • 6.4.6.1 Absorica/Epuris: Sales Forecast 2017-2027
    • 6.4.7 Ziana (clindamycin/tretinoin) - Valeant Pharmaceuticals International
      • 6.4.7.1 Valeant's Patent Settlement with Actavis over Ziana
      • 6.4.7.2 Ziana: Sales Forecast 2017-2027
    • 6.4.8 Doryx (doxycycline) - Actavis/Mayne Pharma
      • 6.4.8.1 Lifecycle Management Strategies for Doryx
      • 6.4.8.2 Divestment Agreement with Mayne Pharma
      • 6.4.8.3 Generic Competition for Doryx
      • 6.4.8.4 Doryx: Sales Forecast 2017-2027
    • 6.4.9 Other Acne Drugs
      • 6.4.9.1 Acanya (clindamycin/benzoyl peroxide) - Dow / Valeant
        • 6.4.9.1.1 Actavis Claims First-to-File Exclusivity for its Acanya ANDA
        • 6.4.9.1.2 Legal Battles Involving Dow/Valeant, Perrigo, and Watson
      • 6.4.9.2 Amnesteem (isotretinoin) - Mylan
        • 6.4.9.2.1 Amnesteem: Financial Analysis
      • 6.4.9.3 Diane (cyproterone/ethinyl estradiol) - Bayer
      • 6.4.9.4 Duac (clindamycin/benzoyl peroxide) - GlaxoSmithKline
      • 6.4.9.5 Veltin (tretinoin/clindamycin) - GSK
      • 6.4.9.6 Other Acne Drugs: Sales Forecast 2017-2027
  • 6.5 Acne Drugs: Market Summary

7. Dermatitis Drugs Market: Market Analysis and Forecast 2017-2027

  • 7.1 Dermatitis Drugs: High Generic Penetration
    • 7.1.1 Leading Products in the Dermatitis Drugs Market, 2016
  • 7.2 Dermatitis Drugs: Market Forecast 2017-2027
    • 7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2017-2027
  • 7.3 Leading Drugs in the Dermatitis Drugs Market
    • 7.3.1 Bepanthen (dexpanthenol)/ Bepanthol - Bayer
      • 7.3.1.1 Bepanthen: Sales Forecast 2017-2027
    • 7.3.2 Elocon (mometasone) - Merck & Co
      • 7.3.2.1 Elocon: Sales Forecast 2017-2027
    • 7.3.3 Protopic (tacrolimus) - LEO Pharma
      • 7.3.3.1 Protopic Benefits from Expanded Indication
      • 7.3.3.2 Generic Competition For Protopic
      • 7.3.3.3 Protopic: Sales Forecast 2017-2027
    • 7.3.4 Dermovate -GSK
      • 7.3.4.1 Dermovate: Sales Forecast 2017-2027
    • 7.3.5 Other Dermatitis Drugs: Sales Forecast 2017-2027
  • 7.4 Dermatitis Drugs: Market Outlook

8. Leading National Markets for Dermatological Drugs, 2017-2027

  • 8.1 The Dermatological Drugs Market by Region
    • 8.1.1 The Global Distribution of Dermatological Drugs in 2016
  • 8.2 Leading National Markets: Forecast 2017-2027
    • 8.2.1 Changing Market Shares by Region, 2016-2027
  • 8.3 Regional Dermatological Drugs Markets: Analysis and Forecasts, 2016-2027
    • 8.3.1 United States: The Largest Dermatological Drugs Market
      • 8.3.1.1 Obamacare Repeal
      • 8.3.1.2 Legislative Environment Stimulating Biosimilars Market?
      • 8.3.1.3 Biosimilar Interchangeability guidance in the US
      • 8.3.1.4 US Dermatological Drugs Market: Market Forecast 2017-2027
    • 8.3.2 The EU5 Markets: Growth Expected in Each Country
      • 8.3.2.1 EU5 Dermatological Drugs Market: Market Forecast 2017-2027
        • 8.3.2.1.1 EU5 Markets: Changing Market Shares by Country, 2016-2027
      • 8.3.2.2 Germany
        • 8.3.2.2.1 German Dermatological Drugs Market: Market Forecast 2017-2027
      • 8.3.2.3 France
        • 8.3.2.3.1 French Dermatological Drugs Market Forecast 2017-2027
      • 8.3.2.4 UK
        • 8.3.2.4.1 The Impact Of Brexit On The Dermatological Drugs Industry
          • 8.3.2.4.1.1 Pricing and Reimbursement
          • 8.3.2.4.1.2 New Regulatory Body and Clinical Trials
          • 8.3.2.4.1.3 Patent Protection
          • 8.3.2.4.1.4 Research and Funding
        • 8.3.2.4.2 UK Dermatological Drugs Market Forecast 2017-2027
      • 8.3.2.5 Italy
        • 8.3.2.5.1 Italian Dermatological Drugs Market Forecast 2017-2027
      • 8.3.2.6 Spain
        • 8.3.2.6.1 Spanish Dermatological Drugs Market Forecast 2017-2027
    • 8.3.3 Japan
      • 8.3.3.1 The Cost of Treatment in Japan
      • 8.3.3.2 Japanese Pharmaceutical Industry Regulatory Reform
      • 8.3.3.3 Japanese Dermatological Drugs Market Forecast 2017-2027
    • 8.3.4 China
      • 8.3.4.1 Expansion of Healthcare Coverage and Reimbursement in China
      • 8.3.4.2 Improving Public Perception of Dermatology in China
      • 8.4.3.3 Price Controls and the Anhui Model
      • 8.3.4.4 Chinese Dermatological Drugs Market Forecast 2017-2027
    • 8.3.5 India
      • 8.3.5.1 The Effects of the Drug Prices Control Order of 2013
      • 8.3.5.2 India's Expansion of Healthcare Provision
      • 8.3.5.3 Revised Biosimilar Guidelines
      • 8.3.5.4 Indian Dermatological Drugs Market Forecast 2017-2027
    • 8.3.6 Brazil
      • 8.3.6.1 The Growth in Brazil's Healthcare Landscape
      • 8.3.6.2 Clearer Access to Medicines in Brazil
      • 8.3.6.3 Brazilian Dermatological Drugs Market Forecast 2017-2027
    • 8.3.7 Russia
      • 8.3.7.1 Pharma2020 Strategy - Healthcare and Industry Reform
      • 8.3.7.2 Russian Dermatological Drugs Market Forecast 2017-2027
    • 8.3.8 Rest of the World
      • 8.3.8.1 The Rest of the World Dermatological Drugs Market Forecast 2017-2027

9. Leading Companies in the Dermatological Drugs Market, 2017-2027

  • 9.1 Dermatological Drugs - A Rapidly Consolidating Market
  • 9.2 Galderma (Nestle Skin Health S.A.)
    • 9.2.1 Galderma: Dermatological Drugs Portfolio, 2017
    • 9.2.2 Galderma: Recent Developments
      • 9.2.2.1 Nestlé's Acquisition of Galderma
      • 9.2.2.2 Approval and Launch of Soolantra for Rosacea
  • 9.3 Johnson & Johnson
    • 9.3.1 Johnson & Johnson: Dermatological Drugs Portfolio, 2016
    • 9.3.2 Johnson & Johnson: Dermatological Drug Development
    • 9.3.2.1 Pipeline, 2017
  • 9.4 AbbVie
    • 9.4.1 AbbVie: Dermatological Drugs Portfolio, 2017
  • 9.5 GlaxoSmithKline (GSK)
    • 9.5.1 GSK: Dermatological Drugs Portfolio, 2017
    • 9.5.3 GlaxoSmithKline (GSK): Recent Developments
    • 9.5.3.1 Business Restructuring Arrangements With Novartis
    • 9.5.4 GlaxoSmithKline (GSK): Dermatological Drugs Development Pipeline, 2016
  • 9.6 Pfizer
    • 9.6.1 Pfizer: Dermatological Drugs Portfolio, 2017
    • 9.6.2 Pfizer: Acquisition of Anacor
    • 9.6.3 Pfizer: Dermatological Drugs Development Pipeline, 2017
  • 9.7 LEO Pharma
    • 9.7.1 LEO Pharma: Dermatological Drugs Portfolio, 2017
    • 9.7.2 LEO Pharma: Dermatological Drugs Development Pipeline, 2017
    • 9.7.3 LEO Pharma: Strategic Partnership with AstraZeneca
    • 9.7.4 LEO Pharma: Acquisition of Astellas Pharma

10. Dermatological Drugs: Research and Development Pipeline, 2017-2027

  • 10.1 Innovative Products Currently in Development Will Drive Growth
    • 10.1.1 New Technology in R&D Pipeline Activities
      • 10.1.1.1 Reformulation
      • 10.1.1.2 Combination Treatments
      • 10.1.1.3 New Mechanisms and Drug Delivery Technologies
      • 10.1.1.4 Potential Market Entrants
  • 10.2 Psoriasis Drugs Development Pipeline, 2017
    • 10.2.1 Psoriasis Drugs in Phase 3 Development or Regulatory Approval Stage
      • 10.2.1.2 CF101 (Piclidenoson) - Can-Fite BioPharma
    • 10.2.2 Psoriasis Drugs in Phase 2 Development
      • 10.2.2.1 LY3009104 (baricitinib) - Incyte/ Eli Lilly
      • 10.2.2.2 PH-10 (Rose Bengal) - Provectus Biopharmaceuticals
    • 10.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical Development
  • 10.3 Skin Infection Drugs Development Pipeline, 2017
    • 10.3.1 Drugs in Phase 3 Development for Skin Infections
      • 10.3.1.1 Baxdela (delafloxacin) - Melinta Pharmaceuticals
      • 10.3.1.2 NB-001 - NanoBio Corporation
      • 10.3.1.3 Luliconazole - Topica Pharmaceuticals
    • 10.3.2 Drugs in Phase 2 Development for Skin Infections
    • 10.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections
  • 10.4 Acne Drugs Development Pipeline, 2017
    • 10.4.1 Drugs in Phase 3 Development for Acne
      • 10.4.1.2 Visonac (photodynamic therapy) - Photocure
    • 10.4.2 Drugs in Phase 2 Development for Acne
    • 10.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne
    • 10.4.4 A Possible Vaccine for Acne
  • 10.5 Dermatitis Drugs Development Pipeline, 2017
    • 10.5.1 Drugs in Phase 3 Development for Dermatitis
      • 10.5.1.1 Toctino (alitretinoin) - GSK
      • 10.5.1.2 Dermadexin and Pruridexin (P3CGM) - Cipher Pharmaceuticals
      • 10.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) - Pierre Fabre
      • 10.5.1.4 REGN668/SAR231893 (dupilumab) - Regeneron/ Sanofi
    • 10.5.2 Drugs in Phase 2 Development for Dermatitis
    • 10.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis
  • 10.6 Other Dermatological Drugs Development Pipeline, 2017
    • 10.6.1 Other Dermatological Drugs: Filed or Recently Launched
      • 10.6.1.1 Actikerall (fluorouracil/salicylic acid) - Almirall
      • 10.6.1.2 Ameluz (5-ALA photodynamic therapy) - Biofrontera
      • 10.6.1.3 Mirvaso (brimonidine) - Galderma
      • 10.6.1.4 Picato (ingenol mebutate) - LEO Pharma
      • 10.6.1.5 Xolair (omalizumab) - Novartis/ Roche
    • 10.6.2 Other Dermatological Drugs: Phase 3 Pipeline Products, 2017
      • 10.6.2.1 CD5024 (ivermectin) - Galderma
      • 10.6.2.2 SR-T100 gel (Solanum incanum extract) - G&E Herbal Biotechnology
    • 10.6.3 Other Dermatological Drugs: Phase 2 Pipeline Products, 2017

11. Qualitative Analysis of the Dermatological Drugs Market, 2017-2027

  • 11.1 Market Factors Influencing Dermatological Drugs
  • 11.2 SWOT Analysis of the Global Dermatological Drugs Market, 2017-2027
    • 11.2.1 Strengths
      • 11.2.1.1 The High Unmet Clinical Need in Dermatology
      • 11.2.1.2 A Healthy Pipeline of Development-Stage Products
      • 11.2.1.3 Strong Industry-Physician Relationships
    • 11.2.2 Weaknesses
      • 11.2.2.1 Limited Efficacy and Adverse Effects May Impact Product Uptake
      • 11.2.2.2 Patient Adherence - A Major Challenge to Treatment Design
      • 11.2.2.3 Impending Patent Expiries and the Challenges Posed by Generic Competition
    • 11.2.3 Opportunities
      • 11.2.3.1 The High-Growth Sectors in Dermatology
      • 11.2.3.2 Personalised Dermatology: Technological Advances in Genomics
      • 11.2.3.3 Advances in Topical Drug Delivery Methods Offers Product Differentiation
      • 11.2.3.4 Consolidation within Dermatology - Opportunity for Synergistic Growth?
    • 11.2.4 Threats
      • 11.2.4.1 Uncertainty Surrounding Reimbursement and Payment Approvals
      • 11.2.4.2 The Rising Cost of Research and Development
      • 11.2.4.3 Downward Pressures on Drug Prices
  • 11.3 Porter's Five Force Analysis of the Global Dermatological Drugs Market, 2017-2027
    • 11.3.1 Threat of New Entrants
    • 11.3.2 Threat of Substitutes
    • 11.3.3 Rivalry among Competitors
    • 11.3.4 Power of Buyers
    • 11.3.5 Power of Suppliers

12. Research Interviews

  • 12.1 Interview with Dr Michael Siegel, Vice President of Research Programs at National Psoriasis Foundation
    • 12.1.1 National Psoriasis Foundation
    • 12.1.2 Future of the Dermatology Drugs Market
    • 12.1.3 Future Developments on Psoriatic Disease Treatment
    • 12.1.4 New Therapies Arising from Stem Cell Research
    • 12.1.5 Limitations and Scope in Developing Biomarkers for Psoriatic Disease
  • 12.2 Interveiw With Guillaume Clement, Executive Vice President, Region EUROPE+, LEO Pharma
    • 12.2.1 LEOPharma
    • 12.2.2 Future of the Dermatology Drugs Market
    • 12.2.3 Trends - Mergers and Acquisitions in the Pharmaceutical Industry
    • 12.2.4 Leo Pharma's Acquisition of Astellas Pharma
    • 12.2.5 Novel Biologic Treatments for Psoriasis, Partnership with AstraZeneca

13. Conclusions

  • 13.1 Overview of Current Market Conditions and Market Forecast, 2016-2027
  • 13.2 Leading Sectors in Dermatological Drugs in 2016
  • 13.3 Leading Regions in the Dermatological Drugs Market in 2016
  • 13.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2017-2027
  • 13.5 What Does the Future Hold For Dermatological Drugs?

14. Glossary

  • Associated Visiongain Reports
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1 Dermatological Drugs Market Forecast by National Markets: Revenue ($bn), AGR (%) and CAGR (%), 2017-2027
  • Table 2.1 Clinical Trial Phases, 2016
  • Table 3.1 The Global Dermatological Drugs Market by Sector: Revenue ($bn) and Market Shares (%), 2016
  • Table 3.2 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 3.3 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2016-2021, 2021-2027, 2016-2021
  • Table 3.4 The Global Dermatological Drugs Market by Sector: Market Share (%), 2016, 2021 and 2027
  • Table 4.1 Top Drugs in The Psoriasis Drugs Market: Revenue ($bn) and Market Shares (%), 2016
  • Table 4.2 Psoriasis Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.3 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2016, 2021 and 2027
  • Table 4.4 Humira Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
  • Table 4.5 Humira AbbVie Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.6 Stelara Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
  • Table 4.7 Stelara Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.8 Enbrel Historical Sales by Company: Revenue ($bn) and AGR (%), 2008-2016
  • Table 4.9 Enbrel Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.10 Remicade Historical Sales: Revenue ($bn), 2010-2016
  • Table 4.11 Remicade Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.12 Taltz: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.13 Otezla Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.14 Cosentyx Psoriasis Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 4.15 Other Psoriasis Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.1 Top Drugs in the Skin Infection Drugs Market: Revenue ($bn) and Market Share (%), 2016
  • Table 5.2 Skin Infection Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.3 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2016, 2021 and 2027
  • Table 5.4 Cubicin Sales Forecast: Revenue($bn), AGR (%) and CAGR(%), 2016-2027
  • Table 5.5 Zyvox: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
  • Table 5.6 Zyvox: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.7 Canesten: Historical Sales: Revenue ($bn), and AGR (%), 2011-2015
  • Table 5.8 Canesten: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.9 Valtrex: Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
  • Table 5.10 Valtrex: Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.11 Bactroban: Historical Sales: Revenue ($bn) and AGR (%), 2010-2013
  • Table 5.12 Bactroban Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 5.13 Lamisil Novartis Sales Forecast: Revenue ($bn), AGR (%), and CAGR (%), 2016-2027
  • Table 5.14 Other Skin Infection Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.1 Top Drugs in The Acne Drugs Market: Revenue ($bn) and Market Share (%), 2016
  • Table 6.2 Acne Drugs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2016, 2021 and 2027
  • Table 6.4 Epiduo (Galderma/ Nestlé) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.5 Solodyn (Valeant) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.6 Claravis (Teva) Sales Forecast: Revenue ($bn), AGR%, and CAGR (%), 2016-2027
  • Table 6.7 Aczone (Allergan) Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.8 Differin (Galderma/ Nestlé) Sales Forecast: Revenue ($bn), AGR (%) and CAGR%), 2016-2027
  • Table 6.9 Absorica/Epuris Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%),
  • 2016-2027
  • Table 6.10 Ziana Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.11 Doryx Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 6.12 Other Acne Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.1 Top Drugs in The Dermatitis Drugs Market: Revenue ($bn) and Market Share (%), 2016
  • Table 7.2 Dermatitis Drugs Market: Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2016, 2021, 2027
  • Table 7.4 Bepanthen/Bepanthol Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.5 Elocon Sales Forecast: Revenue ($bn), AGR (%) CAGR (%), 2016-2027
  • Table 7.6 Protopic Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.7 Dermovate Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 7.8 Other Dermatitis Drugs Sales Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.1 The Global Dermatological Drugs Market by Region: Market Size ($bn) and Market Share (%), 2016
  • Table 8.2 Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2016-2027
  • Table 8.3 The Global Dermatological Drugs Market Forecast by Region: CAGR (%), 2016-2021, 2021-2027, and 2016-2027
  • Table 8.4 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2016, 2021 and 2027
  • Table 8.5 The US Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.6 US Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.7 The EU5 Dermatological Drugs Market by Country Revenue ($bn) and Market Share (%), 2016
  • Table 8.8 The EU5 Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.9 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2016, 2021 and 2027
  • Table 8.10 The German Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.11 The German Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.12 The French Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.13 The French Dermatological Drugs Market Forecast: Revenue ($bn, AGR (%)and CAGR (%), 2016-2027
  • Table 8.14 The UK Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.15 The UK Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.16 The Italian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.17 The Italian Dermatological Drugs Market Forecast: ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.18 The Spanish Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.19 The Spanish Dermatological Drugs Market Forecast: Revenue($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.20 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.21 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.22 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.23 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn, AGR (%) and CAGR (%), 2016-2027
  • Table 8.24 The Indian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.25 The Indian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.26 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2015-2026
  • Table 8.27 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.28 The Russian Dermatological Drugs Market Forecast: Revenue ($bn), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.29 The Russian Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 8.30 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn), Market Share (%) and CAGR (%), 2016-2027
  • Table 8.31 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2027
  • Table 9.1 Galderma: Company Overview, 2016
  • Table 9.2 Johnson & Johnson: Company Overview, 2016
  • Table 9.3 AbbVie: Company Overview, 2017
  • Table 9.4 GlaxoSmithKline: Company Overview, 2016
  • Table 9.5 GlaxoSmithKline: Dermatological Drugs Pipeline, 2016
  • Table 9.6 Pfizer: Company Overview, 2016
  • Table 9.7 LEO Pharma: Company Overview, 2016
  • Table 10.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 10.3 Psoriasis Drugs Pipeline: Phase 1 and Pre-Clinical Drugs, 2016
  • Table 10.4 Skin Infections Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.5 Skin Infections Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 10.6 Acne Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.7 Acne Drugs Pipeline: Phase 2 Drugs, 2015
  • Table 10.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 10.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2016
  • Table 10.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2016
  • Table 10.12 Other Dermatological Drugs Pipeline: Phase 2 Drugs, 2016
  • Table 11.1 SWOT Analysis of the Global Dermatological Drugs Market, 2016-2026
  • Table 12.1 Global Dermatological Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2016, 2021 and 2027
  • Table 12.2 The Global Dermatological Drugs Market by Sector: Market Size ($bn) and Market Shares (%), 2016
  • Table 12.3 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2016, 2021 and 2027
  • Table 12.4 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), 2016, 2021, 2027

List of Figures

  • Figure 1.1 Global Dermatological Drugs Market: Market Sectors, 2017
  • Figure 2.1 Anatomy of Human Skin
  • Figure 3.1 The Global Dermatological Drugs Market by Sector: Revenue ($bn), 2016
  • Figure 3.2 The Global Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%) 2016-2027
  • Figure 3.3 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2016-2021
  • Figure 3.4 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2021-2027
  • Figure 3.5 The Global Dermatological Drugs Market Forecast by Sector: CAGR (%), 2016-2027
  • Figure 3.6 The Global Dermatological Drugs Market by Sector: Market Share (%), 2016
  • Figure 3.7 The Global Dermatological Drugs Market by Sector: Market Share (%), 2021
  • Figure 3.8 The Global Dermatological Drugs Market by Sector: Market Share (%), 2027
  • Figure 4.1 Top Drugs in The Psoriasis Drugs Market: Revenue ($bn), 2016
  • Figure 4.2 Psoriasis Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.3 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2016
  • Figure 4.4 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%) by Leading Drugs, 2021
  • Figure 4.5 The Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2027
  • Figure 4.6 Humira Historical Sales: Revenue ($bn) AGR (%), 2010-201
  • Figure 4.7 Humira AbbVie Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.8 Stelara Historical Sales: Revenue ($bn) and AGR (%), 2010-2015
  • Figure 4.9 Stelara Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.10 Enbrel Historical Sales by Company: Revenue ($bn), 2008-2015
  • Figure 4.11 Enbrel Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.12 Remicade Historical Sales: Revenue ($bn) and AGR (%), 2008-2016
  • Figure 4.13 Remicade Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.14 Taltz Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.15 Otezla Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.16 Cosentyx Psoriasis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 4.17 Other Psoriasis Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.1 Top Drugs in the Skin Infection Drugs Market: Revenue ($bn), 2016
  • Figure 5.2 Skin Infection Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.3 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2016
  • Figure 5.4 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2021
  • Figure 5.5 The Global Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2027
  • Figure 5.6 Cubicin Sales Forecast: Revenue ($bn) AGR (%), 2016-2027
  • Figure 5.7 Zyvox: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
  • Figure 5.8 Zyvox: Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.9 Canesten: Historical Sales: Revenue ($bn) and AGR (%), 2011-2014
  • Figure 5.10 Canesten: Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.11 Valtrex: Historical Sales: Revenue ($bn) and AGR (%), 2010-2014
  • Figure 5.12 Valtrex Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.13 Bactroban: Historical Sales: Revenue ($bn) AGR (%), 2010-2013
  • Figure 5.14 Bactroban Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.15 Lamisil Novartis Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 5.16 Other Skin Infection Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.1 Top Drugs in The Acne Drugs Market: Revenue ($bn), 2016
  • Figure 6.2 Acne Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2016
  • Figure 6.4 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2021
  • Figure 6.5 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2027
  • Figure 6.6 Epiduo (Galderma/ Nestlé) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.7 Solodyn (Valeant) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.8 Claravis (Teva) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.9 Aczone (Allergan) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.10 Differin (Galderma/ Nestlé) Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.11 Absorica/Epuris Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.12 Ziana Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.13 Doryx Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 6.14 Other Acne Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.1 Top Drugs in The Dermatitis Drugs Market: Revenue ($bn), 2016
  • Figure 7.2 Dermatitis Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2016
  • Figure 7.4 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2021
  • Figure 7.5 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2027
  • Figure 7.6 Bepanthen/ Bepanthol Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.7 Elocon Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.8 Protopic Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.9 Dermovate Sales Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 7.10 Other Dermatitis Drugs Sales Forecast: Revenue ($bn) and AGR (%), 2015-2026
  • Figure 8.1 The Global Dermatological Drugs Market by Region: Market Size ($bn), 2016
  • Figure 8.2 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2016
  • Figure 8.3 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2021
  • Figure 8.4 The Global Dermatological Drugs Market Forecast by Region: Market Share (%), 2027
  • Figure 8.5 US Dermatological Drugs Market Forecast: Revenue ($bn) AGR (%), 2016-2027
  • Figure 8.6 The EU5 Dermatological Drugs Market by Country: Revenue ($bn), 2016
  • Figure 8.7 Germany, France, UK, Italy, and Spain Dermatological Drugs Market Forecast: Revenue ($bn), 2016-2027
  • Figure 8.8 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2016
  • Figure 8.9 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2021
  • Figure 8.10 The EU5 Dermatological Drugs Market by Country: Market Share (%), 2027
  • Figure 8.11 The German Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.12 The French Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.13 The UK Dermatological Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 8.14 The Italian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.15 The Spanish Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.16 The Japanese Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.17 The Chinese Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.18 The Indian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.19 The Brazilian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.20 The Russian Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 8.21 The Rest of the World Dermatological Drugs Market Forecast: Revenue ($bn) and AGR (%), 2016-2027
  • Figure 11.1 Porter's Five Force Analysis of the Dermatological Drugs Market, 2016
  • Figure 12.1 Global Dermatological Drugs Market Forecast: Revenue ($bn), 2016, 2021, 2027
  • Figure 12.2 The Global Dermatological Drugs Market by Sector: Market Size ($bn), 2016
  • Figure 12.3 The Global Dermatological Drugs Market Forecast by Sector: Revenue ($bn), 2016, 2021, 2027

Companies Listed

  • Abbott
  • AbbVie
  • Actavis
  • AET BioTech
  • Alkem Laboratories
  • Allergan
  • Almirall
  • Amgen
  • Anacor
  • Ascend Therapeutics
  • Astellas
  • Aurovindo
  • Barr Labs
  • Bayer
  • Betta Pharmaceuticals
  • Biocon/Mylan
  • Biofrontera
  • Biogen
  • Biovail Laboratories
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Brazilian Society of Dermatology
  • Cadila Healthcare
  • Can-Fite BioPharma
  • Cassiopea SpA
  • Celgene
  • Celltrion
  • Cempra
  • Cipher Pharmaceuticals
  • Cipla
  • Cubist Pharmaceuticals
  • Cutanea Life Sciences
  • Dow Pharmaceuticals Science
  • Dr Reddy's
  • Durata Therapeutics
  • Eisai
  • Eli Lilly
  • European Medicines Agency (EMA)
  • European Pharmaceutical Market Research Association (EPhMRA)
  • Food and Drug Association (FDA)
  • Foamix
  • Fougera
  • Fujifilm
  • G&E Herbal Biotechnology
  • Galderma
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Heritage
  • Impax
  • Incyte
  • Janssen Biotech
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • L'Oreal
  • LEO Pharma
  • Lupin
  • Maruho
  • Mayne Pharma
  • Medicis
  • Medison Pharma
  • Melinta Pharmaceuticals
  • Merck
  • Merz Pharmaceuticals
  • Mitsubishi Tanabe
  • MorphoSys
  • Mylan
  • NanoBio Corporation
  • National Psoriasis Foundation (NPF)
  • NeoStrata Compnay Inc
  • Nestle Skin Health
  • Novan
  • Novartis
  • Perriogo
  • Pfizer
  • PharmaPraxis
  • Photocure
  • Pierre Fabre
  • Provectus Biopharmaceuticals
  • QLT Inc
  • Ranbaxy
  • Regeneron Pharmaceuticals
  • Roche
  • Samsung Bioepis
  • Samsung BioLogics
  • Sandoz
  • Sanofi
  • Schering-Plough
  • Shanghai CP Buojian Pharmaceutical
  • Sidmak Labs
  • Sol-Gel Technologies Ltd
  • Sun Pharma
  • Sunovion
  • Takeda
  • Tanabe
  • Tanja Todberg
  • Taro Pharmaceuticals
  • Teva
  • Thesan Pharmaceuticals Inc
  • Topica Pharmaceuticals
  • UCB
  • Valeant
  • Vical
  • Warner Chilcott
  • Watson Pharmaceuticals
  • Xenon Pharmaceuticals
  • Zydus
Back to Top